| Literature DB >> 28813520 |
Azar Dokht Khosravi1,2, Moloudsadat Motahar2, Effat Abbasi Montazeri2.
Abstract
BACKGROUND: Pseudomonas aeruginosa is an opportunistic pathogen with the ability to cause severe nosocomial infections and remains a major problem in burn patients. This organism shows a remarkable antimicrobial resistance and is often resistant to multiple antibiotics. Integron genes as mobile genetic elements are playing an important role in the spread of P. aeruginosa antibiotic resistance. This study was aimed to investigate the occurrence of class 1, and 2 integron genes (int1, int2), among P. aeruginosa strains isolated from patients with burn infections.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28813520 PMCID: PMC5557579 DOI: 10.1371/journal.pone.0183061
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Sequences of primers used for detection of integrase genes.
| Target gene | Primer sequence(5´→3´) | Size(bp) | Annealing Temprature (°C) |
|---|---|---|---|
| 160 | 59 | ||
| 789 | 59 | ||
Prevalence of P. aeruginosa isolates in different hospital departments according to the type of clinical samples.
| Sample No. (%) | |||||||
|---|---|---|---|---|---|---|---|
| Wound | Blood | Biopsy | Urine | Stool | Ear | Catheter | |
| ICU | 33(35.48) | 10(10.75) | 4(4.3) | - | - | - | 1(1.08) |
| Internal (W) | 16(17.2) | 3(3.23) | 3(3.23) | - | - | - | - |
| Plastic surgery | 8(8.6) | 1(1.08) | - | 1(1.08) | 1(1.08) | 1(1.08) | - |
| Internal(M) | 5(5.38) | - | - | 3(3.23) | - | - | - |
| Pediatrics | 3(3.23) | - | - | - | - | - | - |
ICU: Intensive Care Unit; W: women; M: men
Fig 1Antimicrobial resistance pattern of P. aeruginosa isolates.
GM: Gentamicin, CIP: Ciprofloxacin, MEM: Meropenem, CRO: ceftriaxone; AK: Amikacin, PTZ: Pipracillin/Tazobactam, IMI: Imipenem, CAZ: ceftazidime; COL: Colistin.
Association between presence of integron and antibiotic resistance among 93 P. aeruginosa clinical isolates.
| Antibiotics | Integron positive isolates (n = 89) | Integron-negative isolates (n = 4) | P value | ||||
|---|---|---|---|---|---|---|---|
| R No. (%) | I No. (%) | S No. (%) | R No. (%) | I No. (%) | S (%) | ||
| 88(98.88) | 0 | 1(1.12) | 0 | 0 | 4(100) | 0.001 | |
| 87(97.75) | 0 | 2(2.25) | 0 | 0 | 4(100) | 0.001 | |
| 84(94.38) | 1(1.12) | 4(4.49) | 0 | 0 | 4(100) | 0.001 | |
| 82(92.13) | 2(2.25) | 5(5.62) | 0 | 0 | 4(100) | 0.001 | |
| 82(92.13) | 1(1.12) | 6(6.74) | 0 | 0 | 4(100) | 0.001 | |
| 81(91.01) | 3(3.37) | 5(5.62) | 0 | 0 | 4(100) | 0.001 | |
| 78(87.64) | 5(5.62) | 6(6.74) | 0 | 0 | 4(100) | 0.001 | |
| 28(31.46) | 3(3.37) | 58(65.17) | 0 | 0 | 4(100) | 0.352 | |
| 0 | 0 | 89(100) | 0 | 0 | 4(100) | NS |
GM:gentamicin; CIP: ciprofloxacin; MEM: meropenem; CRO: ceftriaxone; AK: amikacin; PTZ: Pipracillin/tazobactam; IMI: imipenem; CAZ: ceftazidime; COL: colistin. R: resistant; I: intermediate; S:sensitive; NS: not statistically significant